Pharma shakeups put pressure on top brass at Amgen to perform
With activist investor Bill Ackman pushing to buy Botox maker Allegran in a bid with upstart Valeant and restructurings under way at pharma giants GlaxoSmithKline, Eli Lilly & Co. and Novartis, it’s logical to question whether biotech giant Amgen will be next. So far the answer seems to be “not yet” — with one big Read More →
Amgen pays $290M to exit osteoporosis drug deal
Amgen will pay $290 million to end its collaboration with British drugmaker GlaxoSmithKline to commercialize the osteoporosis drug denosumab in certain markets outside the U.S.
Ceres to plow $23M raise into sorghum tests
Thousand Oaks-based energy crop firm Ceres has raised $23 million that it hopes will help it to break even as it continues testing its seeds in Brazil.
Thousand Oaks law seminars focus on big questions in biotech
Organizers promise a steady progression from relatively anodyne topics like 3-D printers and intellectual property to touchier subjects, such as genetically engineered salmon, how animals are treated in biotech research and what ethical and legal obligations biotech researchers have when they appropriate and commercialize molecules traditionally used by indigenous cultures.
Ceres files for $20M offering
The Thousand Oaks-based firm said it would like to use the proceeds from the public offering to expand its Brazilian operations, participate in collaborations and break into new markets.
